This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 18, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NasdaqGS: GERN) (CUSIP: 374163103). Investors are advised to contact
Robert S. Willoughby at
email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether Geron and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
March 12, 2014, the Company announced that it has received verbal notice from the U.S. Food and Drug Administration ("FDA") that its investigational new drug application for its experimental drug, imetelstat for blood disorders, has been placed on full clinical hold, affecting its mid-stage trials of imetelstat because of low-grade liver function test abnormalities.
On this news, shares of Geron fell
$1.69, or more than 61.59%, on unusually heavy trading volume, on
March 12, 2014.
The Pomerantz Firm, with offices in
San Diego, and
Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late
Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See
CONTACT: Robert S. Willoughby Pomerantz LLP
SOURCE Pomerantz LLP